

**PERSONAL
INFORMATION****Evelina Tacconelli**✉ evelina.tacconelli@univr.it**PUBBLICAZIONI**

Numero totale di pubblicazioni in riviste peer-reviewed: 426
Numero totale di citazioni: 33.343 (Google Scholar)
Indice H: 80 (Google Scholar)

**CAMPI DI
INTERESSE**

Medicina personalizzata nelle malattie infettive, Gestione degli antibiotici (Antibiotic Stewardship), Gestione della diagnostica per le malattie infettive (Diagnostic Stewardship), Resistenza antimicrobica (impatto ed epidemiologia), Controllo e prevenzione delle infezioni, Infezioni nei pazienti immunocompromessi, COVID-19, Medicina basata sull'evidenza.

ATTIVITA' Professionali

Dal 5/2023	Chief Scientific Officer di ECRAID (European Clinical Research Alliance on Infectious Diseases), Utrecht, Netherlands
Dal 10/ 2018	Direttore della UOC di Malattie Infettive, Università di Verona, UNIVR; ID-CARE (Infectious Diseases Centre for TrAnslational REsearch), UNIVR
Dal 10/ 2017	Professore ordinario, Malattie Infettive, UNIVR
Dal 01/ 2021	Lecturer on Antimicrobial Resistance, DZIF Research Clinical Unit on healthcare associated infections and antimicrobial resistance, Infectious Diseases, Dept. Internal Medicine I, Tübingen University, Germany
2013 - 2020	Direttore della Divisione di Malattie Infettive, Dipartimento Medicina Interna I, University Hospital Tübingen University, Germania
2012 – 2020	Direttore della DZIF Research Clinical Unit on healthcare associated infections and antimicrobial resistance, Tübingen University, Germania
2012 – 2017	Professore ordinario, Malattie Infettive, University of Tübingen, Germania
2013 - 2018	Direttore Medico del Comprehensive Center for infectious Diseases, University Hospital Tübingen
2003 - 2007	Lecturer on Medicine, Infectious Diseases, BIDMC and Harvard Medical School, Boston, USA
1999 - 2013	Ricercatore di Malattie Infettive, Università Cattolica Sacro Cuore, Roma
1997 - 1999	Specializzazione in Malattie Infettive, Università Cattolica Sacro Cuore, Roma

EDUCAZIONE

09/1986 - 07/1992	Laurea in Medicina e Chirurgia (09/1986 –07/1992; 110/110 cum laude), Università Cattolica di Roma, Rome, Italy
09/1992 - 07/1996	Ricercatore di Malattie Infettive, Università Cattolica Sacro Cuore, Roma (60/60 cum laude)
09/1997 - 06/1998	Master per Operatori di Sanità Pubblica, Università la Sapienza, Rome, Italy

Riconoscimenti

2024	ESCMID (European Society of Clinical Microbiology and Infectious Diseases) Excellence Lifetime Achievement Award
2023	Forbes Fellow, Australasian Society for Infectious Diseases
2020	"Lowbury Lecture 2020 for Excellence in Research in Prevention of Healthcare Associated Infections", Hospital Infections Society, UK
2020	Profile eminent ID specialists: Lancet Infectious Disease Oct 2020: E Tacconelli, two viruses, two wars
2019-2025	Presente nell'elenco pubblico dei 100.000 migliori scienziati al mondo
2004	"Young Investigator Award for Clinical Microbiology and Infectious Diseases" European Society of Clinical Microbiology and Infectious Diseases
2003	"Young Investigator Award for the Study on Antibiotic Resistance". Slovak Society of Chemotherapy, Slovakia
1998	"Junior Scholarship Award, University of London, for Curricula Studiorum and Abstract Presentation at 4 th International Congress on Drug Therapy in HIV Infection", Glasgow.
1997	National scholarship for studies on AIDS, National Institute of Health, Italy

EDITORIAL BOARDS (selezione)

Dal 2020	Senior Editor, Journal of Antimicrobial Chemotherapy
Dal 2014	Scientific Committee, Clinical Microbiology and Infection
Dal 2012	International Advisory Board, Lancet Infectious Diseases
2009 - 2019	Editorial Board, Journal of Antimicrobial Chemotherapy
2004 - 2013	Associated Editor, Clinical Microbiology and Infection

SOCIETA' SCIENTIFICHE e BOARD (selezione)

Dal 2023	WHO R&D of Antibacterial Treatments, expert member
Dal 2022	Cohort Coordination Board (in collaboration with the European Commission), coordinator
2022	AMR stockpiling study group (public health with the European Commission), expert member
2021-2024	Coordinator of the national working group on improving antibiotics' prescriptions, AIFA
Dal 2021	Veneto Region Working Group, Italy – Infectious Diseases Priority Plan, expert member
Dal 2021	Working Group for the coordination of the national plan on antimicrobial resistance (PNCAR, Minister of Health), expert member
2021-2024	ESCMID guidelines for the prevention of surgical site infections, Chairman
2021-2022	ESCMID guidelines for screening policies for healthcare workers to reduce the spread of SARS-CoV-2, Chairperson
2021-2023	Working group for the treatment of COVID-19 with monoclonal antibodies, Veneto Region, expert member
2021	Working group for the treatment of COVID-19 with monoclonal antibodies, Minister of Health, expert member
Dal 2020	Scientific and Technical Committee for controlling SARS-COV-2 infection of Veneto Region, expert member
Dal 2024	EUCIC Working Group on Guidelines, Chairman
2020	Working Group for appropriateness of hospital admission of patients with COVID-19 therapy (National Agency for Regional Health Services, AGENAS), expert member

2020-2024	Scientific Committee for prevention and therapy of SARS-CoV-2 infection, Veneto Region, Italy, expert member
2020-2021	WHO Expert Group on Identifying Priority Fungal Pathogens, expert member
Dal 2019	Regional Committee for the implementation of antimicrobial stewardship by national plan on antimicrobial resistance recommendations, Veneto Region, Chairman
2019-2024	World Health Organisation (WHO) Essential Medicine List, Antibiotics Working Group, expert member
2019	Selection Committee for the Department of Health and Social Care Antimicrobial Resistance Research Capital Funding Competition, NHS, United Kingdom (Capital: £32 million), Coordinator Deputy
Dal 2019	Master on Nursing Specialist on epidemiological surveillance and control of health-care associated infections, University of Verona, Italy, Coordinator
2018-2022	Scientific Board of JPI-AMR (Joint Programming Initiative on Antimicrobial Resistance, European Commission), expert member
Dal 2018	Regional Therapeutic Committee, expert member, Veneto Region, Italy
Dal 2018	Scientific Committee, expert member, IRCCS Sacro Cuore – Don Calabria, Negrar, Italy.
2015-2024	Chair of EUCIC (European Committee of Infection Control)
Dal 2022	ESCMID guidelines to control of hospital spreading of multidrug-resistant gram-negative bacteria, Chairman
2009-2018	European Center for Diseases Control (ECDC) Consultant for antibiotic stewardship and AMR
2018 - 2019	WHO Priority List of antimicrobial resistant bacteria for R&D of effective antibiotics, Chairman
2017 - 2019	ESCMID guidelines Officer of Infectious Diseases and Clinical Microbiology
2016 - 2019	ESCMID guidelines for decolonisation of MDR gram-negative bacteria, Chairman
2009 - 2017	ESCMID Education Officer of Infectious Diseases and Clinical Microbiology
2014 - 2017	Clinical Advisory Board, HZI (Helmholtz Zentrum für Infektionsforschung, Germany), expert member
2014 - 2016	Advisory Board, expert member, German Society for Infectious Diseases, DGI (Deutsche Gesellschaft für Infektiologie, Germany)
2009 - 2013	Study Group on Antibiotic Resistance in Hospitalised Patients, SIMIT, Chairman
2012 - 2013	External Affairs Committee, expert member, SHEA (Society of Healthcare Epidemiologists of America)
2012 - 2013	ESCMID Study Group on Infections in the Elderly (ESGIE), Chairman
2008 - 2012	ISC (International Society of Chemotherapy) Working Group on MRSA - Risk assessment, Chairman

Date	Progetti nazionali e internazionali	Sponsor	Ruolo – budget Università / budget totale, €
2025 - 2027	BE-Ready NOW	HorizonEurope	Partner €800.000/ €100.000.000
2025 - 2028	FAIR: Public health value, cost-effectiveness Analysis and modelling of Reserve antibiotics	GARDP	Coordinator €785.900
2024 - 2028	PIPELINE: Pregnancy and Infant Preparedness Platform IN Europe	HorizonEurope	Partner €110.000/ €9.999.973
2024 - 2029	EU-PROACT: A European Proactive Adaptive Clinical Trials Network	HorizonEurope	Partner €202.406/ €17.042.172
2023 - 2026	COMECT: COordination MEchanism for Cohorts and Trials	HorizonEurope	Partner €451.875/ €3.055.297

2022 - 2023	CLEARER: Current cLinical scEnARios for the use of cefidErocol in multidrug-Resistant infections	GARDP	Coordinator €65.000
2022 - 2023	Update the 2017 WHO BPPL for research and development of new antibacterial treatments.	WHO	Coordinator €118.000
2021 - 2025	VERDI: SARS-CoV2 variants evaluation in pregnancy and paediatrics cohorts.	HorizonEurope	Partner € 355.000/€15.395.599
2021 - 2023	Adaptive group sequential randomized control trial (Phase III) to assess the efficacy of mAb	AIFA	Coordinator € 839.095
2021 - 2026	PRIMAVERA: Vaccines And Monoclonal antibodies: Predicting the Impact on AMR and an Economic evaluation.	IMI	Partner € 280.275 / € 9.250.000
2021 - 2023	AMMURAVID: Factorial, multicentre, randomized clinical trial of Remdesivir and immunotherapy	AIFA	Coordinator
2021 - 2024	VACCELERATE-Italy: European Corona Vaccine Trial Accelerator Platform.	Horizon2020	National Coordinator € 92.361 / € 29.967.975
2021 - 2026	ECRAID BASE: European Clinical Research Alliance on Infectious Diseases	Horizon2020	Partner € 999.815/ € 29.969.875
2021 - 2026	REVERSE: Prevention and management tools for reducing antibiotic Resistance in high prevalence	Horizon2020	National Coordinator € 2.017.882 / € 13.953.194
2020 - 2024	ORCHESTRA: Connecting European Cohorts to Increase Common and Effective Response to SARS.	Horizon2020	Coordinator € 2.204.998 / € 27.887.540
2020 - 2022	WHO Solidarity Trial: international clinical trial to help find an effective treatment for COVID-19.	WHO	In-kind contribution
2020 - 2022	ENACT: Alliance against COVID-19.	Fondazione CariVerona	WP leader € 886.234
2020 - 2025	EU-RESPONSE: European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases.	Horizon2020	National Coordinator € 217.047 / € 15.719.450
2020 - 2021	SARS-CoV-2 Surveillance in school and public places.	CORIS Regione Veneto	Partner € 338.000
2019 - 2021	Development of a web tool to perform surveillance connected to antibiotic prescription in hospital and community.	CORIS Regione Veneto	Coordinator € 210.000
2019 - 2024	VALUE DX – : The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use.	IMI	WP leader € 83.705 / € 6.799.100
2019 - 2023	Factors And Barriers for Preparation of a Phase 3 RCS with ExPEC10V in Adults Aged 60-85 Years With UTI.	IMI	Partner € 1.109.716 / € 83.033.010
2019	Systematic review to develop a WHO Index integrated in the AWARE index to measure optimal antibiotic usage	WHO	Coordinator € 21.000
2019	WHO Tender: Duration of antibiotic therapy to treat community acquired pneumonia.	WHO	Coordinator € 22.000
2019	DZIF-PREDICT Validation of the BLOOMY score for mortality.	DZIF	Coordinator € 89.900
2019-2022	COMBACTE-MAGNET Understanding of the epidemiology and clinical impact of CDI	IMI	Partner € 2.294.881 / € 75.340.000
2020- 2023	SENTINELLA: Rapid identification of SARS-CoV-2 in vulnerable population	Fondazione Veronese	Coordinator € 737.640
Dal 2019	BIOSTEPS: Personalised surgical prophylaxis in pancreatic surgery in high AMR prevalence	AIFA	Partner € 100.000
2018-2021	Understanding and modelling reservoirs, vehicles and transmission of ESBL-Ent. in the community and LTCF.	Horizon 2020	WP leader € 680.000

2018-2020	Combination therapy to treat sepsis due to carbapenem-Resistant bacteria in adult and paediatric population	GARDP	Coordinator € 120.000
2015-2020	DZIF-R-Net Surveillance for antibiotic resistant infections	DZIF	Partner € 95.900
2012-2020	DZIF (German Center for Infectious Diseases Research) CT for research on prevention and treatment of HAIs	DZIF	Coordinator € 1.101.000
2018-2019	Increasing communication, awareness and data sharing in a global approach against resistance	JPI-AMR	In-kind contribution
2018-2019	GAP-One Project: "Global Antimicrobial resistance Platform for ONE Burden Estimates".	JPI-AMR	In-kind contribution
2018-2019	ARCH Project: Bridging the gap between human and animal surveillance data, antibiotic policy, and stewardship. Design: Consensus-driven guidelines development and research priority setting.	JPI-AMR	Coordinator € 50.000
2016-2019	Surveillance of multidrug resistant bacteria in human and animal in Baden Württemberg	Baden-Württemb.	Coordinator € 340.000
2015-2019	DZIF-ABSOLUTE Antimicrobial stewardship to reduce resistance	DZIF	Partner € 99.700
2015-2019	DZIF-BLOOMY Solution for the improvement of bloodstream infections	DZIF	Coordinator € 72.600
2017-2018	Burden of antibiotic resistant infection (GLASS initiative)	WHO	Coordinator € 35.000
2016-2018	IMI-2016-COMBACTE-MAGNET- ICU-ASPIRE	IMI	Partner € 89.000
2014-2018	DRIVE-AB (IMI-2014): "Driving reinvestment in R&D and appropriate usage of antibiotics	IMI	Partner € 373.600
2016-2017	Priority list for AMR pathogens for the R&D for new antibiotics.	WHO	Coordinator € 144.000
2012-2015	DZIF-ATHOS Antimicrobial stewardship in community and healthcare facilities.	DZIF	Partner € 63.000
2012-2015	DZIF- SPECTRUM- Risk factors for Clostridium difficile at hospital admission"	DZIF	Partner € 60.000
2012-2015	"Excellence in Research in Infectious Diseases", University of Tübingen.	EKUT	Coordinator € 240.000
2010-2014	SATURN: impact of specific antibiotic therapies on the prevalence of human host resistant bacteria.	FP7	WP leader € 848.000
2011-2013	Preserving old antibiotics for the future: assessment of clinical efficacy by a PK/P	FP7	Partner € 264.640
2010-2013	European Grant DG Sanco Implementing Strategic Bundles for Infection Prevention & Management	DG Sanco	Partner € 87.156

10 pubblicazioni selezionate

1. Carrara E, .. Tacconelli E. How to tailor recommendations on the treatment of multi-drug resistant Gram-negative infections at country level integrating antibiotic stewardship principles within the GRADE-ADOLOPMENT framework. Lancet Infect Dis. 2024 Feb;24(2):e113-e126 (Impact Factor 25,07)
2. Tacconelli E, et al. Development and validation of BLOOMY prediction scores for 14-day and 6-month mortality in hospitalized adults with bloodstream infections: a multicenter, prospective, cohort study. Lancet Infect Dis 2021, Dec 1-12 (Impact Factor 25,07)
3. Carrara E, .. Tacconelli E. ESCMID guidelines on testing for SARS-CoV-2 in asymptomatic individuals to prevent transmission in the health care setting. Clin Microbiol Infect. 2022 Feb (Impact Factor 8,06)
4. Tacconelli E, et al. Surveillance for control of antimicrobial resistance. Lancet Infect Dis 2017, Oct, 1-8 (Impact Factor 25,07)

5. Tacconelli E, et al. Discovery, research and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria. *Lancet Infect Dis.* 2018 Mar;18(3):318-327. (Impact Factor 25,07; **3150 citations**)
6. Savoldi A, ... Tacconelli E. Prevalence of Antibiotic Resistance in *Helicobacter pylori*: A Systematic Review and Meta-Analysis in World Health Organization Regions J of Gastroenterology 2018 (Impact Factor 22,6; 520 citations)
7. Tacconelli E et al. Fighting the enemy within. *Science* 2017 Feb 17;355(6326):689-690. (Impact Factor 13,08)
8. Baur D, ... Tacconelli E. Effect of antibiotic stewardship on the incidence of infection and colonization with antibiotic-resistant bacteria and *Clostridium difficile* infection: a systematic review and meta-analysis. *Lancet Infect Dis.* 2017 Sep;17(9):990-1001. (Impact Factor 25,07; citations 487)
9. Tacconelli E, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. *Clin Microbiol Infect.* 2014 Jan;20 Suppl 1:1-55. (Impact Factor 8,06; 660 citations)
10. Tacconelli E, et al. Rapid screening tests for methicillin-resistant *Staphylococcus aureus* at hospital admission: systematic review and meta-analysis. *Lancet Infect Dis.* 2009 Sep;9(9):546-54. (Impact Factor 25,07; citations 519)

Autorizzo il trattamento dei miei dati personali ai sensi del D.Lgs. n. 101 del 10/08/2018, "Adeguamento al Regolamento UE 2016/679" e successive modifiche e integrazioni, limitatamente agli scopi per i quali questo CV è stato inviato.

Dichiaro l'assenza di conflitto di interessi in ambito sanitario negli ultimi due anni dalla data di sottoscrizione.

Dichiaro la veridicità dei dati ai sensi degli artt. 19, 46, 47 e 76 del D.P.R. 28 dicembre 2000, n. 445 e la consapevolezza delle sanzioni penali, nel caso di dichiarazioni non veritiere, di formazione o uso di atti falsi.

Verona, 23/02/2025

Evelina Tacconelli